TVTX Q4 2023 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M-19.3% YoY

Gross Profit

$29M63.6% margin

Operating Income

-$83M-183.8% margin

Net Income

-$90M-200.1% margin

EPS (Diluted)

$-1.18

QoQ Revenue Growth

+21.5%

Cash Flow

Operating Cash Flow

-$70M

Free Cash Flow

-$76M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$789M

Total Liabilities

$588M

Stockholders' Equity

$201M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$56M	-19.3%
Gross Profit	$29M	$54M	-47.1%
Operating Income	-$83M	-$67M	-23.9%
Net Income	-$90M	-$66M	-37.0%

Revenue Segments

License

$15M100%